
Life Sciences
Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.
Boston Business Watch reported on Rezera Inc. on October 7, 2026.
October 7, 2026
Boston-based Rezera Inc. said on October 7, 2026 that its experimental oral drug ruvonoflast produced added reductions in an inflammation marker when given alongside the weight-loss drug semaglutide, according to a company announcement distributed by GlobeNewswire. Rezera said the combination was generally well tolerated, with no new safety signals.

Life Sciences
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.